Yesterday, Terns Pharmaceuticals, a phase I/II CML company, accepted an acquisition offer from Merck. The price was USD6.7bn. This underlines the high valuations in the CML space and validates Mendus' CML programme.
ANNONS
Yesterday, Terns Pharmaceuticals, a phase I/II CML company, accepted an acquisition offer from Merck. The price was USD6.7bn. This underlines the high valuations in the CML space and validates Mendus' CML programme.
